Merck KGaA Flags 2026 Earnings Drop as Mavenclad Faces Generics
Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple sclerosis…
Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple sclerosis…